Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryoport, Inc. on June 16, 2014. The filing reports a corporate governance event: the election of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Ramkumar Mandalam, Ph.D., to the Board of Directors. Dr. Mandalam brings experience in biotechnology and cell-based therapies from his roles at Cellerant Therapeutics, Inc., Geron Corporation, and Aastrom Biosciences.
Compensation and Governance
- Role: Non-employee Director, member of the Compensation Committee and Nomination and Governance Committee.
- Equity Compensation: Initial grant to purchase 100,000 shares of common stock.
- Cash Compensation: $40,000 annually.
- Related Party Transactions: None reported.
Investor Verification Checklist
- Verify the vesting schedule and exercise price for the 100,000 share option grant.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the appointment.
- Confirm the total number of outstanding shares to assess the dilution impact of the new grant.
- Check subsequent filings for any changes to the Board composition or committee assignments.